September 13, 2019
Catalyst backs from offering common stock shares
Catalyst Pharmaceuticals, said Friday it will not conclude the offering of shares of its common stock announced on Wednesday, September…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Firdapse
January 4, 2019
Catalyst Pharmaceuticals’ Firdapse tablets meet endpoints in Phase II trial
Catalyst Pharmaceuticals Phase IIb clinical trial for Firdapse tablets, published in SAGE Open Medicine, for the treatment of MuSK antibody positive Myasthenia Gravis (MuSK-MG), has given evidence that amifampridine phosphate was safe and effective in treating MuSK-MG patients.
December 15, 2016
Catalyst Pharmaceuticals begin testing its orphan drug on first patients
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, has announced…
November 10, 2016
Catalyst Pharmaceuticals finishes Q3 2016 with net loss
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating …